Metformin, a pill that lowers blood sugar in people with diabetes, might also reduce their risk of developing glaucoma, an eye disease that can lead to vision loss and blindness, a new study suggests. While the results can’t prove the drug prevents glaucoma, researchers found that diabetics taking higher doses of metformin were less likely […]

Sanofi and its subsidiary Genzyme said on Thursday that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to olipudase alfa. This enzyme replacement therapy is being investigated for the treatment of patients with nonneurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease Type B, as opposed to type […]

THOUSAND OAKS, Calif., June 2, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced a collaboration with Roche on a Phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen’s investigational oncolytic immunotherapy, in combination with Roche’s investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal […]

Drugmakers including Bristol-Myers Squibb Co and Merck & Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Bristol’s Opdivo and Merck’s Keytruda are both therapies designed to block […]

The U.S. Food and Drug Administration said a panel of experts would discuss a marketing application from Eli Lilly & Co on a new targeted lung cancer treatment. The FDA said the panel would review data that showed improved overall survival rate in lung cancer patients treated with a combination of Lilly’s experimental drug, necitumumab, […]

A drug to increase sexual desire in women showed a statistically significant benefit, according to a preliminary review by the U.S. Food and Drug Administration, but the agency raised concerns about an increased risk of fainting and falling blood pressure. “The fundamental question is whether these observed placebo-corrected treatment effects outweigh the risks associated with […]

The genetically altered, cancer-killing T-cells known as CARTs showed dramatic results in non-Hodgkin lymphoma as the two leading players, the Swiss drug giant Novartis and the Seattle upstart Juno Therapeutics, pushed forward with new clinical trials. The new results are to be presented at the annual meeting of the American Society of Clinical Oncology by […]

Former chief scientific officer for Shire Pharmaceuticals and Relmada Therapeutics also headed R&D for Adolor and Stem Cells, Inc.; a trained psychiatrist and CNS specialist, Dr. Salinas arrives as Turing readies clinical trial programs NEW YORK (June 1, 2015) – Turing Pharmaceuticals AG announced that life sciences executive and medical researcher Eliseo Oreste Salinas, MD, MSc,  […]

The National Cancer Institute in July will start enrolling patients in a clinical trial seeking to match the underlying genetic defect driving a person’s tumor with one or more of 20 approved or experimental drugs targeting that gene.  The announcement, made at the American Society for Clinical Oncology meeting on Monday, is meant to use […]

The head of Merck KGaA’s healthcare division said she expected its cancer drug avelumab, jointly developed with Pfizer, to be among the first two or three to market in a field of immunotherapy pharmaceuticals that harness the power of the immune system in a range of cancer types. Other developers of immunotherapy drugs have won […]